- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05093322
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors or lymphoma. The study will be conducted in 2 parts:
Part 1 - evaluation of tolerability and safety of surufatinib administered in combination with gemcitabine, and confirmation of the recommended clinical dose of surufatinib in pediatric patients with recurrent or refractory solid tumors or lymphoma.
Part 2 - evaluation of anti-tumor activity and confirmation of tolerability of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory osteosarcoma, Ewing sarcoma, RMS, and non-RMS.
Part 1 will enroll 2 to 6 patients per dose level cohort (up to 4 cohorts) with recurrent or refractory solid tumors. During cycle 1, surufatinib will be administered, orally, once daily (QD), as a single agent for 14 days followed by surufatinib daily in combination with gemcitabine intravenously on days 15 and 22 (cycle 1 duration=35 days) and days 1 and 8 of all subsequent cycles (cycle duration=21 days). Assessment based on dose limiting toxicity (DLT) criteria will be performed in the first 35-day cycle (DLT Evaluation Period). This study will utilize a rolling 6 design for part 1, with 3 dose escalation levels and 1 de escalation level, if needed.
Part 2 of the study will use a Simon 2-stage design with a maximum of 18 patients per cohort (osteosarcoma, Ewing sarcoma, RMS, and non-RMS). Surufatinib will be administered orally at identified MTD/RP2D daily in combination with gemcitabine (1000 mg/m2 weekly × 2 doses) intravenously on days 1 and 8.
In both parts 1 and 2, patients can remain on treatment until completing cycle 17, or until progressive disease, unacceptable toxicity, or death; whichever comes first.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Expanded Access
Contacts and Locations
Study Contact
- Name: Nicholas Lawn
- Phone Number: +1 973.826.2891
- Email: nickl@hutch-med.com
Study Contact Backup
- Name: John Kauh
- Phone Number: +1 .973.306.4490
- Email: johnk@HUTCH-MED.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Children's Hospital of Alabama
-
-
California
-
Orange, California, United States, 92868
- Childrens Hospital Orange County
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Texas
-
Dallas, Texas, United States, 75390
- The University of Texas Southwestern Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Age: At time of study enrollment, patients must be
- Part 1 (including PK expansion cohort): ≥2 and ≤21 years of age;
- Part 2: ≥2 and ≤21 years of age;
- Patients with osteosarcoma can enroll up to <30 years old.
Diagnosis:
- Part 1 - Patients with any recurrent or refractory solid tumors or lymphoma (not central nervous system [CNS]) that have a known or expected dysfunction of VEGFR 1, -2, and -3; FGFR-1, or CSF-1R pathways (based on literature) are eligible. Patients must have had histologic verification of malignancy at original diagnosis or relapse.
- Part 2 - Recurrent or refractory osteosarcoma (US and EU), Ewing sarcoma (US and EU), RMS (US and EU), or NRSTS (EU only). Patients must have had histologic verification of malignancy at original diagnosis or relapse.
- Disease status: Patients must have measureable or evaluable disease for part 1 dose escalation; for part 2, patients must have measurable disease by RECIST version 1.1.
- Therapeutic options: Patient's current disease state must be one for which there is no known curative therapy.
- Performance level: Karnofsky ≥50 for patients ≥16 and <18 years of age and Lansky ≥50 for patients <16 years of age, Eastern Cooperative Oncology Group (ECOG) ≤2 for patients ≥18 years of age.
- Adequate organ and bone marrow function as defined in the current protocol.
- Adequate cardiac function as indicated as defined in the current protocol.
- Patients with known bone marrow metastatic disease will be eligible for the study provided they meet the blood counts in the inclusion criteria as defined in the current protocol.
- Adequate BP control which is defined as a BP <95th percentile (≤ grade 1) for age, height, and sex.
- Informed consent: Provision of signed and dated written informed consent (parent/legal guardian if patient <18 years of age) and assent (from patients aged >7 years) prior to any study-specific procedures, sampling, and analyses.
- Patient must meet all defined Inclusion criteria as defined in the current protocol.
Exclusion Criteria:
- Patient must not meet any exclusion criteria as defined in the current protocol.
- Pregnant, breast feeding or planning on becoming pregnant.
- Patients is taking and prohibitive concomitant medications as outlined in the current protocol.
- Patients have an uncontrolled infection.
- Patients has had major surgery or significant traumatic injury within 28 days of the first dose.
- Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy and without clinical imaging evidence of SD for 14 days or longer.
- History of allergies to Surufatinib and/or Gemcitabine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1- Dose escalation
Dose escalation study with sequential dose escalation of surufatinib in combination with gemcitabine.
Patients with any recurrent or refractory solid tumors or lymphoma, who have a known or expected dysfunction of VEGFR-1, -2, and -3; FGFR-1; or CSF-1R pathways may be enrolled.
|
Surufatinib in combination with Gemcitabine
Other Names:
|
Experimental: Part 2 - Dose expansion
Once the MTD/RP2D has been determined in the part 1 portion of the study, the part 2 disease specific cohorts for patients with refractory or recurrent osteosarcoma, Ewing Sarcoma, and RMS and non- RMS will open for enrollment.
|
Surufatinib in combination with Gemcitabine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Number of patients with Dose-Limiting Toxicity (DLT) at each dose level studied.
Time Frame: up to 90 days
|
To determine maximum tolerated dose of surufatinib in combination with gemcitabine
|
up to 90 days
|
Part 1: Number of patients with treatment-emergent adverse events as assessed by CTCAE v5.0
Time Frame: up to 4 years
|
To determine the safety and tolerability of surufatinib in combinations with gemcitabine
|
up to 4 years
|
Part 2: To study the rate of patients who have achieved Complete Response (CR) or Partial Response (PR) in pediatric patients with Ewing sarcoma, Rhabdomyosarcoma (RMS), or Non-RMS (NRSTS) treated with the combination of surufatinib and gemcitabine.
Time Frame: up to 4 years
|
The rate of patients who have achieved CR or PR will be reported.
|
up to 4 years
|
Part 2: To study the Time to Response (TTR) of the combination of surufatinib and gemcitabine in pediatric patients with Ewing sarcoma, RMS, or NRSTS.
Time Frame: up to 4 years
|
The time to CR or PR will be reported.
|
up to 4 years
|
Part 2: To study the duration of response (DoR) of the combination of surufatinib and gemcitabine in pediatric patients with Ewing sarcoma, RMS, or NRSTS.
Time Frame: up to 4 years
|
The duration of CR or PR will be reported.
|
up to 4 years
|
Part 2: To study the progression-free survival (PFS) of the combination of surufatinib and gemcitabine in pediatric patients with Ewing sarcoma, RMS, or NRSTS.
Time Frame: up to 4 years
|
The time from enrollment in the clinical trial to disease progression or death will be reported.
|
up to 4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate number of patients with treatment-emergent adverse events as assessed
Time Frame: up to 4 years
|
To evaluate the safety in the pediatric patient population when treated with the combination of surufatinib and gemcitabine
|
up to 4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Josephine Haduong, Children's Hospital of Orange County
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Myosarcoma
- Sarcoma
- Sarcoma, Ewing
- Osteosarcoma
- Rhabdomyosarcoma
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Gemcitabine
Other Study ID Numbers
- 2020-012-GLOB2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
Ruijin HospitalThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsNot yet recruitingLymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-TypeChina
Clinical Trials on Surufatinib in combination with Gemcitabine
-
Rui-hua Xu, MD, PhDNot yet recruitingAdvanced Pancreatic CancerChina
-
PfizerTerminatedNon-small Cell Lung Cancer | Urothelial CancerSpain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
-
HutchmedNot yet recruiting
-
RemeGen Co., Ltd.Recruiting
-
Cyteir Therapeutics, Inc.Active, not recruitingSoft Tissue Sarcoma | Follicular Lymphoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Multiple Myeloma | Pancreatic Cancer | Ovarian Cancer | Mantle Cell Lymphoma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | DLBCL | Non-hodgkin Lymphoma | Malignancy | CLLUnited States
-
Shen LinUnknownColorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2China
-
Hunan Province Tumor HospitalNot yet recruitingNon-small Cell Lung CancerChina
-
Hunan Province Tumor HospitalNot yet recruitingNon-Small Cell Lung CancerChina
-
AkesoNot yet recruiting
-
Sun Yat-sen UniversityRecruitingPeripheral T-cell LymphomaChina